Definium Therapeutics (DFTX) Income from Continuing Operations (2019 - 2026)
Definium Therapeutics (DFTX) reported Income from Continuing Operations of 56963000.0 for Q1 2026, down 87.82% year-over-year from 467796876.25 in Q1 2025, and down 25.54% quarter-over-quarter from 45373000.0 in Q4 2025.
Definium Therapeutics (DFTX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 7 years of Income from Continuing Operations data on file, last reported at 56963000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 56963000.0, down 87.82% year-over-year; the trailing twelve-month figure through Mar 2026 was 187484000.0 (down 80.3% YoY), and the FY2025 annual result was 160849000.0, down 69.96% from the prior year.
- Income from Continuing Operations retreated to 56963000.0 in Q1 2026 per DFTX's latest filing, from 45373000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 56860000.0 in Q4 2022 and troughed at 56963000.0 in Q1 2026.
- A 5-year average of 23333941.18 and a median of 21808000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations jumped 104.95% in 2022, then slumped 137.83% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 56860000.0 in 2022, then sank by 137.83% to 21510000.0 in 2023, then slumped by 38.72% to 29839000.0 in 2024, then tumbled by 52.06% to 45373000.0 in 2025, then dropped by 25.54% to 56963000.0 in 2026.
- Business Quant data shows DFTX's Income from Continuing Operations at 56963000.0 in Q1 2026, 45373000.0 in Q4 2025, and 44681000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Definium Therapeutics | 2.46 Bn | 2.09 Bn | - | -56.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.96 Mn |
| Dec 31, 2025 | -45.37 Mn |
| Sep 30, 2025 | -44.68 Mn |
| Jun 30, 2025 | -40.47 Mn |
| Mar 31, 2025 | -30.33 Mn |
| Dec 31, 2024 | -29.84 Mn |
| Sep 30, 2024 | -22.01 Mn |
| Jun 30, 2024 | -21.81 Mn |
| Mar 31, 2024 | -20.98 Mn |
| Dec 31, 2023 | -21.51 Mn |
| Sep 30, 2023 | -20.18 Mn |
| Jun 30, 2023 | -27.87 Mn |
| Mar 31, 2023 | -19.58 Mn |
| Dec 31, 2022 | 56.86 Mn |
| Sep 30, 2022 | -16.49 Mn |
| Jun 30, 2022 | -16.96 Mn |
| Mar 31, 2022 | -18.51 Mn |
| Dec 31, 2021 | 27.74 Mn |
| Sep 30, 2021 | -17.20 Mn |
| Jun 30, 2021 | -45.25 Mn |